-
Eris Lifesciences acquires Biocon Biologics India branded formulation business for Rs 1242 crore
15 Mar 2024 10:11 GMT
… has announced the acquisition of Biocon Biologics' India branded … Swiss Parenterals business. The Biocon product range can be … long-term collaboration with Biocon which is an organisation … (#5 among Diabetologists and Cardiologists) and strong cash.
-
Biocon Limited enters into a commercialization agreement with Zentiva in Europe
24 Nov 2022 06:13 GMT
… therapeutic areas, including diabetes, cardiology, respiratory and oncology. With … Officer and Managing Director, Biocon Ltd, said, " … Head - Generic Formulations, Biocon Ltd, added. " … This partnership will help Biocon to achieve its strategic …
-
Biocon appoints Susheel Umesh as CCO, Emerging Markets
02 Mar 2021 09:30 GMT
… Executive Officer.
With this appointment, Biocon Biologics will move its commercial … .”
Dr Arun Chandavarkar, Managing Director, Biocon Biologics said, “We are extremely … therapy areas, including diabetes, oncology, cardiology and transplantation, and has a …
-
Biocon Pharma and DKSH Collaborate to commercialize seven generic formulations in South East Asia markets
22 Jun 2020 06:50 GMT
… diabetology, cardiology, oncology and immunology, which will be sold under Biocon… for Biocon's products in several therapeutic areas, such as cardiology … patient needs in diverse markets. Biocon has successfully commercialized a few …
-
Biocon to expand generic drugs business with DKSH
22 Jun 2020 13:35 GMT
… cardiology, oncology and immunology, which will be sold under Biocon’s … officer and managing director, Biocon.
DKSH will manage marketing … in multiple markets, said Biocon in a press release.
… DKSH, was quoted saying.
Biocon has commercialized a few products …
-
Biocon Ltd. ADR (BCNQY) CEO Siddharth Mittal on Q3 2020 Results - Earnings Call Transcript
24 Jan 2020 13:01 GMT
… global markets for the products.
Biocon and Equillium expanded their collaborational … are 2 companies, Biocon Biologics Limited and Biocon Biologics India Limited. As … of oncology of diabetes and cardiology with our statins portfolio, immunosuppressants …
-
Biocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner Libbs
29 Dec 2017 06:46 GMT
… cancer patients immensely."
Biocon and Mylan are responsible for … European Free Trade Association countries. Biocon has co-exclusive commercialization rights … including gynecology, central nervous system, cardiology, oncology and dermatology. Libbs…
-
Biocon to sell Parit in India after Eisai ends 12-year partnership with GSK
29 Mar 2017 04:57 GMT
… marketing these brands since 2005.
Biocon will market the two rabeprazole … of branded formulations business of Biocon said: “These products will … target customers comprising diabetologists and cardiologists. These specialties have immense potential …
-
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
29 Feb 2024 06:12 GMT
… in the field of cardiology, including interventional cardiology, heart disease prevention, … the biosimilars business to Biocon Biologics Limited ("Biocon Biologics") in … of the biosimilars business to Biocon Biologics in November 2022, Complex …
-
Implantable Drug Delivery Devices Global Market to Exhibit Growth at a Considerable CAGR of ~6% by 2028, Assesses DelveInsight
24 Jan 2024 06:19 GMT
… Market Segmentation By Application: Oncology, Cardiology, Gynecology, Auto-Immune Diseases, and … , including Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West …